We are proud to be a global leader in early-phase clinical trials, with dedicated facilities across Australia, the United States and the United Kingdom, and a unified approach that delivers speed, safety, and quality on both sides of the world.
Together with our clients, we’re not just conducting trials, we’re fulfilling our purpose:
With facilities in Australia, the US and the UK, Nucleus Network is the only global early-phase specialist of its kind. Since 1993, we’ve conducted over 2,500 trials for leading biotech and pharmaceutical companies around the world.
Our Australian Phase I clinics are located in Melbourne and Brisbane, with our US site in Minneapolis and our UK site in London.
Together, these facilities offer more than 300 beds and are strategically co-located within world-class medical, research, and biotech precincts: The Alfred Hospital in Melbourne, Royal Brisbane and Women’s Hospital in Brisbane, Medical Alley in Minnesota and Central Middlesex Hospital in London.
These locations give Nucleus Network direct access to specialized expertise, equipment and infrastructure essential for complex early-phase trials. From first-in-human PD studies supported by advanced systems in Melbourne, to purpose-built biosimilar capabilities in Brisbane and onsite dialysis for renal studies in Minneapolis, and full service capabilities for phase 1 and early phase 2 trials in London. Our global network is equipped to deliver even the most demanding early-phase clinical research.
At Nucleus Network, participant safety is at the core of everything we do. Our clinical trials are led by Board Certified Physicians who serve as Principal Investigators, bringing advanced medical oversight to each study.
With experienced teams based in Brisbane, Melbourne, Minneapolis and London, our investigators collaborate closely on complex early-phase clinical trials including first-in-human, ensuring consistent safety standards and delivering exceptional medical insight to support our clients’ success.
